KPV is a tripeptide (Lysine-Proline-Valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). While alpha-MSH is known for its melanogenic (skin tanning) effects, KPV retains the potent anti-inflammatory properties of the parent hormone without causing skin darkening. KPV is a powerful anti-inflammatory peptide that works by inhibiting NF-kB signaling, the master regulator of inflammatory gene expression. It has shown remarkable efficacy in preclinical studies for inflammatory bowel disease, skin inflammation, and systemic inflammatory conditions. It is increasingly popular as a natural anti-inflammatory alternative.
Notes
KPV is a research peptide not approved by the FDA for any indication. All data comes from preclinical studies and anecdotal user reports. The anti-inflammatory mechanism through NF-kB inhibition is well-characterized in cell and animal models.
KPV exerts its anti-inflammatory effects primarily through inhibition of the NF-kB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) signaling pathway. NF-kB is the master transcription factor controlling the expression of hundreds of pro-inflammatory genes including TNF-alpha, IL-1beta, IL-6, IL-8, COX-2, and iNOS. By entering the cell nucleus and directly blocking NF-kB activation, KPV broadly suppresses the inflammatory cascade at its source. Unlike NSAIDs which only block COX enzymes, or biologics which target single cytokines, KPV inhibits the upstream regulator of virtually all inflammatory mediators. It also modulates antimicrobial peptide expression in intestinal epithelial cells, supporting gut barrier function.
KPV is a small tripeptide (3 amino acids) with favorable pharmacokinetic properties for its size. It is absorbed rapidly after subcutaneous injection with peak levels in 30-60 minutes. Its small size allows some degree of oral absorption, making oral dosing viable particularly for GI-targeted effects. The peptide crosses cell membranes to access intracellular NF-kB signaling. Metabolism is through standard peptidase activity. The biological anti-inflammatory effects persist beyond plasma clearance due to downstream gene expression changes.
Typical Dose
Subcutaneous: 200-500 mcg per day. Oral: 500-1000 mcg per day (for GI-specific inflammation). Topical: applied in cream/serum form to affected areas. Most common protocol: 500 mcg subcutaneous injection once daily.
Frequency
Once daily for subcutaneous injection. Once or twice daily for oral or topical use.
Administration
Subcutaneous injection (systemic anti-inflammatory use), oral capsules (for GI inflammation/IBD), or topical application (for skin inflammation). Oral bioavailability is enhanced by its small size and stability. Subcutaneous injection provides the most reliable systemic levels.
Half-Life
2-4 hours (estimated from peptide fragment pharmacokinetics)
Contraindications
No PCT required. KPV has no effect on the hormonal system or HPTA.